rss
BMJ Case Reports 2009; doi:10.1136/bcr.09.2008.0994
  • Novel treatment (new drug/intervention; established drug/procedure in new situation)

The impact of tuberculosis treatment on glycaemic control and the significant response to rosiglitazone

  1. Augusto Pimazoni
  1. Medical Coordinator of the Diabetes Education and Control Groups at the Kidney and Hypertension Hospital, Federal University of São Paulo, and at the Diabetes Center, Oswaldo Cruz German Hospital, Sao Paulo, Brazil
  1. Augusto Pimazoni, pimazoni{at}uol.com.br
  • Published 17 April 2009

Summary

This case involves a 43-year-old female patient with highly uncontrolled type 2 diabetes for the past 14 years. Her weekly mean (SD) glycaemia (WMG) concentration at week 1 was 20.9 (4.8) mmol/l (377 (87) mg/dl). Four weeks after reaching full control at week 3 with insulin glargine plus regular insulin and metformin (WMG 7.0 (1.9) mmol/l (127 (34) mg/dl)) she was diagnosed with acute pulmonary tuberculosis and treated with rifampicin, isoniazid and pyrazinamide, which caused her to lose glycaemic control (WMG 21.0 (7.1) mmol/l (378 (128) mg/dl)). No other potentially hyperglycaemic drug such as corticosteroid was used. During this entire period she was intensively treated with NPH (neutral protamine Hagedorn) and regular insulins, reaching a total daily dose of 170 IU, but with no clinical response. Together with insulin therapy, rosiglitazone was started at week 12 and glycaemic control returned to normal within just 3 weeks (WMG 6.6 (2.9) mmol/l (120 (53) mg/dl)).

Footnotes

  • Competing interests: none.

  • Patient consent: Patient/guardian consent was obtained for publication

Register for free content

The full text of all Editor's Choice articles and summaries of every article are free without registration

The full text of Images in ... articles are free to registered users

Only fellows can access the full text of case reports (apart from Editor's Choice) - become a fellow today, or encourage your institution to, so that together we can grow and develop this resource

Don't forget to sign up for content alerts so you keep up to date with all the case reports as they are published, and let us know what you think by commenting on the Editor's blog